Study: NCT03419403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid eye drops
Description: Solution, eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid eye drops
Description: Solution, eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid eye drops
Description: Solution, eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasoconstrictor eye drops
Description: Solution, eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasoconstrictor eye drops
Description: Solution, eye drop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold compress
Description: Cold compress

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold compress
Description: Cold compress

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ophthalmic steroid ointment
Description: Ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin
Description: During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin
Description: During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin
Description: During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.